Community Research and Development Information Service - CORDIS

Attacking HIV diseases

Human Immunodeficiency Virus, or simply HIV, has been identified as the key cause of AIDS, which is one of the most life threatening diseases worldwide. Focusing on the development of an effective treatment, a very promising new anti-HIV compound has recently been synthesised and successfully tested in a laboratory environment.
Attacking HIV diseases
According to the latest statistics released from the World Health Organisation, 42 million people live with HIV/AIDS where 38.6 million are adults. Despite the international efforts to control measures against the disease they are still ineffective since only last year 5 million new infections with HIV were recorded. At the same time it is considered as one of the most deadly diseases worldwide and during last year a total of 3.1 million people died of HIV/AIDS related causes.

Aiming at developing more effective drugs, researchers have recently synthesised a family of new compounds called 4-(Arylthio)-pyridin-2(1H)-ones. These compounds display unique properties, including high specificity when inhibiting reverse transcriptase of HIV-1, widely recognised as the most common type species of the virus. HIV-1 reverse transcriptase is an enzyme responsible for the synthesis of DNA from the genomic RNA of the virus. Thereby, these chemicals when broken down may stop HIV-1 from infecting uninfected cells in the body and in this way they limit the extent of the virus spreading.

Fighting this fatal disease, scientists have been trying for many years to develop effective drug therapies against HIV. Having been biologically tested, these novel compounds were found to lead to great reductions of HIV-1 virus activity, even when it was found highly resistant to the commonly used Neviparine drug. Thus, these novel compounds exhibit increased potentialities for use in the design of therapeutic drugs for the treatment of HIV diseases.
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top